XRAY in the 13F filings
Dentsply Sirona Inc · CUSIP 24906P109
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 4 Feb 2026
- Managers listing it
- 30
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 6 listed it in both
- Shares listed
- 39,202,262
- combined, among listed positions
- Reported value
- $448m
- combined, at the quarter end
Among the 92 comparable managers: 23 buyers (opened or added shares) and 9 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -698,498.
Managers listing XRAY in Q4 2025
30 of 30 holders
Largest increases and reductions, by shares
Increases
- Marshall Wace LLPexisting position · 2,236,786 shares now+2,039,280
- D. E. Shaw & Co.existing position · 4,434,744 shares now+1,537,885
- Jane Street Group LLCexisting position · 1,472,736 shares now+1,318,159
- Citadel Advisors LLCexisting position · 1,729,647 shares now+655,904
- Invesco Ltdexisting position · 1,063,523 shares now+534,714
Reductions
- AQR Capital Management LLCexisting position · 4,898,136 shares now-7,602,230
- Millennium Management LLCexisting position · 1,069,704 shares now-1,303,291
- Schonfeld Strategic Advisors LLCexisting position · 56,973 shares now-219,464
- Fidelity (FMR LLC)existing position · 20,707 shares now-64,770
- Brevan Howard Capital Management LPexisting position · 88,363 shares now-17,199
New positions and exits
New (4)
Exited (3)
- Arrowstreet Capital LPwas $3.7m
- Man Group PLCwas $1.8m
- Quantbot Technologies LPwas $865k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2016 | 17 | $3.1bn | n.a. | n.a. |
| Q2 2016 | 18 | $3.0bn | n.a. | n.a. |
| Q3 2016 | 15 | $2.8bn | n.a. | n.a. |
| Q4 2016 | 14 | $2.7bn | n.a. | n.a. |
| Q1 2017 | 19 | $2.7bn | n.a. | n.a. |
| Q2 2017 | 13 | $2.6bn | n.a. | n.a. |
| Q3 2017 | 13 | $2.6bn | n.a. | n.a. |
| Q4 2017 | 12 | $2.6bn | n.a. | n.a. |
| Q1 2018 | 17 | $1.4bn | n.a. | n.a. |
| Q2 2018 | 12 | $933m | n.a. | n.a. |
| Q3 2018 | 18 | $1.6bn | n.a. | n.a. |
| Q4 2018 | 13 | $1.6bn | n.a. | n.a. |
| Q1 2019 | 13 | $1.8bn | n.a. | n.a. |
| Q2 2019 | 14 | $2.1bn | n.a. | n.a. |
| Q3 2019 | 16 | $1.9bn | n.a. | n.a. |
| Q4 2019 | 16 | $2.0bn | n.a. | n.a. |
| Q1 2020 | 16 | $1.5bn | n.a. | n.a. |
| Q2 2020 | 16 | $2.1bn | n.a. | n.a. |
| Q3 2020 | 14 | $2.3bn | n.a. | n.a. |
| Q4 2020 | 11 | $2.7bn | n.a. | n.a. |
| Q1 2021 | 16 | $3.7bn | n.a. | n.a. |
| Q2 2021 | 23 | $3.8bn | n.a. | n.a. |
| Q3 2021 | 18 | $3.3bn | n.a. | n.a. |
| Q4 2021 | 13 | $2.8bn | n.a. | n.a. |
| Q1 2022 | 16 | $2.8bn | n.a. | n.a. |
| Q2 2022 | 18 | $2.0bn | n.a. | n.a. |
| Q3 2022 | 17 | $1.5bn | n.a. | n.a. |
| Q4 2022 | 14 | $1.6bn | n.a. | n.a. |
| Q1 2023 | 11 | $2.2bn | n.a. | n.a. |
| Q2 2023 | 10 | $1.9bn | n.a. | n.a. |
| Q3 2023 | 15 | $1.7bn | n.a. | n.a. |
| Q4 2023 | 13 | $1.7bn | 9 | 7 |
| Q1 2024 | 12 | $1.1bn | 8 | 5 |
| Q2 2024 | 9 | $781m | 7 | 3 |
| Q3 2024 | 8 | $941m | 6 | 2 |
| Q4 2024 | 9 | $648m | 8 | 2 |
| Q1 2025 | 9 | $586m | 8 | 2 |
| Q2 2025 | 8 | $639m | 3 | 6 |
| Q3 2025 | 6 | $369m | 4 | 2 |
| Q4 2025 | 5 | $199m | 23 | 9 |
| Q1 2026 | 7 | $273m | 17 | 17 |
| Q2 2026 | 5 | $61m | 10 | 19 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
XRAY and LLY →XRAY and JNJ →XRAY and VRTX →Choose a stock to compare with XRAY →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own XRAY, latest filings →Back to the 13F Explorer →